What is Kontafarma China Holdings Revenue per Share?
Kontafarma China Holdings's revenue per share for the
six
months ended in Dec. 2023 was HK$0.07.
Kontafarma China Holdings's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.15.
Warning Sign:
Kontafarma China Holdings Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Kontafarma China Holdings was -9.40% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -7.10% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -13.80% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -0.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Kontafarma China Holdings's Revenue per Share or its related term are showing as below:
HKSE:01312'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -27.9 Med: -10.2 Max: 59.9
Current: -7.1
During the past 13 years, Kontafarma China Holdings's highest 3-Year average Revenue Per Share Growth Rate was 59.90% per year. The lowest was -27.90% per year. And the median was -10.20% per year.
HKSE:01312's 3-Year Revenue Growth Rate is ranked worse than 82.1% of 922
companies
in the Drug Manufacturers industry
Industry Median: 6.4
vs HKSE:01312: -7.10
Kontafarma China Holdings Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kontafarma China Holdings's Revenue per Share
For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kontafarma China Holdings's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Kontafarma China Holdings's PS Ratio falls into.
Kontafarma China Holdings Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Kontafarma China Holdings's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kontafarma China Holdings (HKSE:01312) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Kontafarma China Holdings Revenue per Share Related Terms
Thank you for viewing the detailed overview of Kontafarma China Holdings's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Kontafarma China Holdings (HKSE:01312) Business Description
Kontafarma China Holdings Ltd is principally engaged in the manufacture and sale of prescription drugs including chemical drugs and traditional Chinese medicine in the PRC, and the operation of fitness centers, provision of fitness and health consulting services, and the operation of franchises. The operating segments include pharmaceutical business and Fitness business. Majority of its revenue derives from pharmaceutical business segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01312 has been successfully added to your 